title: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
abstract: Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868-3298, USA. Ignatius.ou@uci.edu
authors.forename: Sai-Hong Ignatius
authors.initials: SH
authors.lastname: Ou
authors.forename: Eunice L
authors.initials: EL
authors.lastname: Kwak
authors.forename: Christina
authors.initials: C
authors.lastname: Siwak-Tapp
authors.forename: Joni
authors.initials: J
authors.lastname: Dy
authors.forename: Kristin
authors.initials: K
authors.lastname: Bergethon
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: D Ross
authors.initials: DR
authors.lastname: Camidge
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Solomon
authors.forename: Robert G
authors.initials: RG
authors.lastname: Maki
authors.forename: Yung-Jue
authors.initials: YJ
authors.lastname: Bang
authors.forename: Dong-Wan
authors.initials: DW
authors.lastname: Kim
authors.forename: James
authors.initials: J
authors.lastname: Christensen
authors.forename: Weiwei
authors.initials: W
authors.lastname: Tan
authors.forename: Keith D
authors.initials: KD
authors.lastname: Wilner
authors.forename: Ravi
authors.initials: R
authors.lastname: Salgia
authors.forename: A John
authors.initials: AJ
authors.lastname: Iafrate
mesh_terms: D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077547:Crizotinib; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D005260:Female; D005784:Gene Amplification; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017978:Receptors, Growth Factor / Q000235:genetics*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D017978:Receptors, Growth Factor; D003841:Deoxycytidine; D000068258:Bevacizumab; D000077547:Crizotinib; D016190:Carboplatin; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases; D000093542:Gemcitabine